Nasopharyngeal Microbiota as an early severity biomarker in COVID-19 hospitalised patients. Issue 3 (March 2022)

• Record Type: Journal Article
• Authors: Ventero, Maria Paz; Moreno-Perez, Oscar; Molina-Pardines, Carmen; Paytuví-Gallart, Andreu; Boix, Vicente; Escribano, Isabel; Galan, Irene; González-delaAleja, Pilar; López-Pérez, Mario; Sánchez-Martínez, Rosario; Merino, Esperanza; Rodríguez, Juan Carlos
• Is Part Of: Journal of infection. Volume 84:Issue 3(2022)
• Page Start: 329
• Page End: 336
• Publication Date: 2022-03
• Subjects: Microbiota -- COVID-19 -- SARS-COV-2 -- Severity -- Biomarker -- Prognosis; Infection -- Periodicals; Bacterial Infections -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.905
• DOI: 10.1016/j.jinf.2021.12.030
• Languages: English
• ISSNs: 0163-4453

Abstract

Highlights: Lower microbiota diversity is linked to a worse prognosis, and increased likelihood of a fatal outcome. The presence of Selenomonas SPP., Filifactor SPP., Actinobacillus SPP. or Chroococcidiopsis SPP., is associated with a reduced risk of invasive mechanical ventilation being required. The microbiome could be used as a prognostic factor. Summary: This study aimed to analyse the diversity and taxonomic composition of the nasopharyngeal microbiota, to determine its association with COVID-19 clinical outcome. To study the microbiota, we utilized 16S rRNA sequencing of 177 samples that came from a retrospective cohort of COVID-19 hospitalized patients. Raw sequences were processed by QIIME2. The associations between microbiota, invasive mechanical ventilation (IMV), and all-cause mortality were analysed by multiple logistic regression, adjusted for age, gender, and comorbidity. The microbiota α diversity indexes were lower in patients with a fatal outcome, whereas the β diversity analysis showed a significant clustering in these patients. After multivariate adjustment, the presence of Selenomonas spp., Filifactor spp., Actinobacillus spp., or Chroococcidiopsis spp., was associated with a reduction of more than 90% of IMV. Higher diversity and the presence of certain genera in the nasopharyngeal microbiota seem to be early biomarkers of a favourable clinical evolution in hospitalized COVID-19 patients. Graphical abstract: Image, graphical abstract .